Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH).
Alvarado-Tapias E, Maya-Miles D, Albillos A, Aller R, Ampuero J, Andrade RJ, Arechederra M, Aspichueta P, Banales JM, Blas-García A, Caparros E, Cardoso Delgado T, Carrillo-Vico A, Claria J, Cubero FJ, Díaz-Ruiz A, Fernández-Barrena MG, Fernández-Iglesias A, Fernández-Veledo S, Francés R, Gallego-Durán R, Gracia-Sancho J, Irimia M, Lens S, Martínez-Chantar ML, Mínguez B, Muñoz-Hernández R, Nogueiras R, Ramos-Molina B, Riveiro-Barciela M, Rodríguez-Perálvarez ML, Romero-Gómez M, Sabio G, Sancho-Bru P, Ventura-Cots M, Vidal S, Gahete MD. Alvarado-Tapias E, et al. Among authors: aller r. Gastroenterol Hepatol. 2024 Dec;47(10):502207. doi: 10.1016/j.gastrohep.2024.502207. Epub 2024 May 8. Gastroenterol Hepatol. 2024. PMID: 38723772 Free article. English, Spanish.
Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD.
Muñoz-Hernández R, Gato S, Gil-Gómez A, Aller R, Rojas A, Morán L, Gallego J, Blázquez-López E, Gallego-Durán R, Montero-Vallejo R, García-Fernández V, Maya-Miles D, Rico MDC, Cubero FJ, Vaquero J, Ampuero J, Bañares R, Romero-Gómez M. Muñoz-Hernández R, et al. Among authors: aller r. Liver Int. 2023 Sep;43(9):1909-1919. doi: 10.1111/liv.15604. Epub 2023 Jun 8. Liver Int. 2023. PMID: 37288714
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
Noureddin M, Truong E, Mayo R, Martínez-Arranz I, Mincholé I, Banales JM, Arrese M, Cusi K, Arias-Loste MT, Bruha R, Romero-Gómez M, Iruzubieta P, Aller R, Ampuero J, Calleja JL, Ibañez-Samaniego L, Aspichueta P, Martín-Duce A, Kushner T, Ortiz P, Harrison SA, Anstee QM, Crespo J, Mato JM, Sanyal AJ. Noureddin M, et al. Among authors: aller r. Hepatology. 2024 Jan 1;79(1):135-148. doi: 10.1097/HEP.0000000000000542. Epub 2023 Jul 24. Hepatology. 2024. PMID: 37505221 Free PMC article.
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, Gómez-Camarero J, Caballería J, Lo Iacono O, Ibañez L, García-Samaniego J, Albillos A, Francés R, Fernández-Rodríguez C, Maya-Miles D, Diago M, Poca M, Andrade RJ, Latorre R, Jorquera F, Morillas RM, Escudero D, Hernández-Guerra M, Pareja-Megia MJ, Banales JM, Aspichueta P, Benlloch S, Rosales JM, Turnes J, Romero-Gómez M; HEPAmet Registry. Ampuero J, et al. Among authors: aller r. J Gastroenterol. 2024 Jul;59(7):586-597. doi: 10.1007/s00535-024-02098-8. Epub 2024 Apr 15. J Gastroenterol. 2024. PMID: 38619600 Free PMC article.
Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.
Gallego-Durán R, Ampuero J, Maya-Miles D, Pastor-Ramírez H, Montero-Vallejo R, Rivera-Esteban J, Álvarez-Amor L, Pareja MJ, Rico MC, Millán R, Robles-Frías MJ, Aller R, Rojas Á, Muñoz-Hernández R, Gil-Gómez A, Gato S, García-Lozano M, Arias-Loste MT, Abad J, Calleja JL, Andrade RJ, Crespo J, González-Rodríguez Á, García-Monzón C, Andreola F, Pericás JM, Jalan R, Martín-Bermudo F, Romero-Gómez M. Gallego-Durán R, et al. Among authors: aller r. United European Gastroenterol J. 2024 Oct;12(8):1056-1068. doi: 10.1002/ueg2.12534. Epub 2024 Jun 18. United European Gastroenterol J. 2024. PMID: 38894596 Free PMC article.
One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population.
Iruzubieta P, Mayo R, Mincholé I, Martínez-Arranz I, Arias-Loste MT, Ibañez-Samaniego L, Ampuero J, Abad J, Martín-Mateos R, Fernández-Laso AB, Albillos A, Bañares R, Calleja JL, Romero-Gómez M, Aller R, Crespo J. Iruzubieta P, et al. Among authors: aller r. United European Gastroenterol J. 2024 Sep;12(7):919-929. doi: 10.1002/ueg2.12589. Epub 2024 Aug 4. United European Gastroenterol J. 2024. PMID: 39099245 Free PMC article.
Letter to the Editor: Serum identification of At-Risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
Noureddin M, Truong E, Mayo R, Martínez-Arranz I, Mincholé I, Banales JM, Arrese M, Cusi K, Arias-Loste MT, Bruha R, Romero-Gómez M, Iruzubieta P, Aller R, Ampuero J, Calleja JL, Ibañez-Samaniego L, Aspichueta P, Marín-Duce A, Kushner T, Ortiz P, Harrison SA, Anstee QM, Crespo J, Mato JM, Sanyal AJ. Noureddin M, et al. Among authors: aller r. Hepatology. 2024 Sep 26. doi: 10.1097/HEP.0000000000001061. Online ahead of print. Hepatology. 2024. PMID: 39325967 No abstract available.
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
Armandi A, Sanavia T, Younes R, Caviglia GP, Rosso C, Govaere O, Liguori A, Francione P, Gallego-Duràn R, Ampuero J, Pennisi G, Aller R, Tiniakos D, Burt A, David E, Vecchio F, Maggioni M, Cabibi D, McLeod D, Pareja MJ, Zaki MYW, Grieco A, Stål P, Kechagias S, Fracanzani AL, Valenti L, Miele L, Fariselli P, Eslam M, Petta S, Hagström H, George J, Schattenberg JM, Romero-Gómez M, Anstee QM, Bugianesi E. Armandi A, et al. Among authors: aller r. Gut. 2024 Apr 5;73(5):825-834. doi: 10.1136/gutjnl-2023-330815. Gut. 2024. PMID: 38199805 Free article.
Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol.
Pavlides M, Mózes FE, Akhtar S, Wonders K, Cobbold J, Tunnicliffe EM, Allison M, Godfrey EM, Aithal GP, Francis S, Romero-Gomez M, Castell J, Fernandez-Lizaranzu I, Aller R, González RS, Agustin S, Pericàs JM, Boursier J, Aube C, Ratziu V, Wagner M, Petta S, Antonucci M, Bugianesi E, Faletti R, Miele L, Geier A, Schattenberg JM, Tilman E, Ekstedt M, Lundberg P, Berzigotti A, Huber AT, Papatheodoridis G, Yki-Järvinen H, Porthan K, Schneider MJ, Hockings P, Shumbayawonda E, Banerjee R, Pepin K, Kalutkiewicz M, Ehman RL, Trylesinksi A, Coxson HO; LITMUS Consortium Investigators; Martic M, Yunis C, Tuthill T, Bossuyt PM, Anstee QM, Neubauer S, Harrison S. Pavlides M, et al. Among authors: aller r. Contemp Clin Trials. 2023 Nov;134:107352. doi: 10.1016/j.cct.2023.107352. Epub 2023 Oct 4. Contemp Clin Trials. 2023. PMID: 37802221 Free article.
478 results